Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Hua Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8936-3371; OpenAlex author ID A5088046842. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers

Papers 15

  1. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Last author DOI 10.1002/mc.23936↗
  2. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2025.102301↗
  3. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3. Co-author DOI 10.1016/j.isci.2024.109406↗
  4. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  5. Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological c… Co-author DOI 10.1007/s00259-022-06100-4↗
  6. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the… Co-author DOI 10.1007/s00259-023-06297-y↗
  7. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
  8. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. Co-author DOI 10.1186/s13046-020-01787-5↗
  9. Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13046-021-02152-w↗
  10. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  11. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13046-018-0739-x↗
  12. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. Co-author DOI 10.1186/s13046-016-0406-z↗
  13. MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP. Co-author DOI 10.1371/journal.pone.0116934↗
  14. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Co-author DOI 10.18632/oncotarget.2184↗
  15. S100 family signaling network and related proteins in pancreatic cancer (Review). First author DOI 10.3892/ijmm.2014.1633↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 13 shared papers, 2014–2025 · strength 1.65
  2. Jiangdong Qiu · 6 shared papers, 2021–2025 · strength 0.96
  3. Gang Yang · 6 shared papers, 2018–2024 · strength 0.78
  4. Lei You · 8 shared papers, 2014–2024 · strength 0.76
  5. Zhe Cao · 7 shared papers, 2014–2024 · strength 0.75
  6. Jinxin Tao · 4 shared papers, 2023–2025 · strength 0.71
  7. Yupei Zhao · 7 shared papers, 2014–2024 · strength 0.67
  8. Yueze Liu · 4 shared papers, 2021–2025 · strength 0.67
  9. Wenhao Luo · 4 shared papers, 2021–2025 · strength 0.66
  10. Jianchun Xiao · 4 shared papers, 2021–2025 · strength 0.63
  11. Tao Liu · 2 shared papers, 2024–2025 · strength 0.35
  12. Yifan Fu · 2 shared papers, 2024–2025 · strength 0.35
  13. Zhixin Hao · 2 shared papers, 2023 · strength 0.33
  14. Qiaofei Liu · 2 shared papers, 2023 · strength 0.33
  15. Jie Ding · 2 shared papers, 2023 · strength 0.33
  16. Xiang Li · 2 shared papers, 2023 · strength 0.33
  17. Li Huo · 2 shared papers, 2023 · strength 0.33
  18. Fangyu Zhao · 2 shared papers, 2021–2023 · strength 0.28
  19. Guangyu Chen · 2 shared papers, 2021–2023 · strength 0.28
  20. Guangbing Xiong · 3 shared papers, 2016–2021 · strength 0.26
  21. Mengyu Feng · 2 shared papers, 2018–2021 · strength 0.21
  22. Zhe Cao · 1 shared paper, 2025 · strength 0.20
  23. Hao Chen · 1 shared paper, 2025 · strength 0.20
  24. Yuanyang Wang · 1 shared paper, 2025 · strength 0.20
  25. Jun Wang · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.